Advertisement

Research Article Free access | 10.1172/JCI112983

Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model.

J P Eder, B A Teicher, S A Holden, K N Cathcart, and L E Schnipper

Find articles by Eder, J. in: JCI | PubMed | Google Scholar

Find articles by Teicher, B. in: JCI | PubMed | Google Scholar

Find articles by Holden, S. in: JCI | PubMed | Google Scholar

Find articles by Cathcart, K. in: JCI | PubMed | Google Scholar

Find articles by Schnipper, L. in: JCI | PubMed | Google Scholar

Published May 1, 1987 - More info

Published in Volume 79, Issue 5 on May 1, 1987
J Clin Invest. 1987;79(5):1524–1528. https://doi.org/10.1172/JCI112983.
© 1987 The American Society for Clinical Investigation
Published May 1, 1987 - Version history
View PDF
Abstract

DNA-DNA crosslinks are the lethal cellular mechanism of bifunctional alkylating agent cytotoxicity. Novobiocin, an inhibitor of DNA topoisomerase II, impairs eukaryotic DNA repair of alkylating agent adducts and may increase the number of adducts and their resultant cytotoxicity in malignant cells. The effect of novobiocin on clonogenic survival and DNA crosslinking due to cisplatin (cDDP) and carmustine (BCNU) was studied. Novobiocin caused synergistic cytotoxicity in Chinese hamster ovary cells exposed to cDDP or BCNU. Novobiocin and cDDP increased the formation of DNA-DNA interstrand crosslinks six-fold greater than cDDP alone. The effect was schedule dependent. Novobiocin and cDDP or BCNU markedly reduced in vivo growth of a murine fibrosarcoma without increased host toxicity. As a modulating agent of cytotoxicity due to DNA-DNA crosslinking, novobiocin may enhance the clinical effectiveness of the alkylating agents in human cancer and offer insight into new therapeutic strategies.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (May 1, 1987): No description
Advertisement
Advertisement